VolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a report released on Wednesday. The brokerage issued a sell rating on the stock.

Separately, Benchmark reissued a “hold” rating on shares of VolitionRx in a report on Friday, August 16th.

VolitionRx Stock Down 2.1 %

NYSE VNRX opened at $0.79 on Wednesday. The firm has a market cap of $73.57 million, a P/E ratio of -2.21 and a beta of 1.10. VolitionRx has a 52-week low of $0.43 and a 52-week high of $1.23. The business’s 50-day moving average price is $0.69 and its 200 day moving average price is $0.68.

Institutional Investors Weigh In On VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Geode Capital Management LLC lifted its holdings in shares of VolitionRx Limited (NYSE:VNRX) by 15.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 730,448 shares of the company’s stock after buying an additional 95,900 shares during the period. Geode Capital Management LLC owned about 0.79% of VolitionRx worth $439,000 at the end of the most recent reporting period. 8.09% of the stock is owned by hedge funds and other institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.